Program
belumosudil
Also written as “Belumosudil”, “Belumosudil (KD025)” and “Belumosudil mesylate”.
Its studies are mostly in Bronchiolitis Obliterans Syndrome · Immune System Diseases · Scleroderma, Diffuse · Autoimmune Diseases · Psoriasis, led by 2 companies.
Drug pageBelumosudil: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 256 open or running | phase 4since Sep 24, 2024 | Apr 2, 2014 | Jan 26, 2027phase 1 · NCT07726914 |
| BioNova Pharmaceuticals (Shanghai) | 10 open or running | phase 2since Jun 11, 2021 | Jun 11, 2021 | none ahead |
Also a collaborator on its studies: Meiji Seika Pharma and Quotient Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of BioNova Pharmaceuticals (Shanghai) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2020Named belumosudilINNProposed as its International Nonproprietary Name in WHO's List 123 · before, KD025
- Jun 11, 2021First study: phase 2 study in Bronchiolitis Obliterans SyndromeFirst studyNCT04930562 · 30 enrolled · China
TargetBeta
“An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), ”NCIt, by rule
“Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| netarsudilrule | Alcon | phase 4 | 20 |
Studies
The one study BioNova Pharmaceuticals (Shanghai) leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04930562Bronchiolitis Obliterans Syndrome · China | 2 | Completed | Jun 10, 2022 | 30 |
How it is read
Names in the registry
- “Belumosudil”, 15 entries
- “Belumosudil (KD025)”, 3 entries
- “Belumosudil mesylate”, 3 entries
- “KD025”, 2 entries
- “Belumosudil 200 mg QD”, 1 entry
Conditions, from the studies’ own filings
- Bronchiolitis Obliterans Syndrome, 10 studies
- Immune System Diseases, 3 studies
- Scleroderma, Diffuse, 2 studies
- Autoimmune Diseases, 2 studies
- Psoriasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.